|
Patent landscape, scope, and claims: |
Analyzing the Scope and Claims of United States Patent 8,679,532
Introduction
United States Patent 8,679,532, titled "Amikacin Liposome Inhalation Suspension," is a significant patent held by Insmed Incorporated. This patent is part of a broader portfolio related to the company's product Arikayce® (Amikacin Liposome Inhalation Suspension). Here, we will delve into the details of this patent, including its scope, claims, and the broader patent landscape.
Patent Overview
Patent Number and Expiration
- The patent number is 8,679,532, and it is set to expire on December 5, 2026[2].
Invention Description
- The patent pertains to an Amikacin Liposome Inhalation Suspension, which is a formulation designed for the treatment of certain bacterial infections, particularly in patients with cystic fibrosis or other respiratory conditions. The invention involves liposomes that encapsulate the antibiotic amikacin, enhancing its delivery and efficacy when inhaled[2].
Scope of the Patent
Technical Field
- The patent falls under the technical field of pharmaceutical formulations, specifically inhalation therapies. It is classified under relevant International Patent Classification (IPC) categories related to pharmaceutical compositions and drug delivery systems[4].
Claims
- The patent includes multiple claims that define the scope of the invention. These claims typically cover the composition of the liposome formulation, the method of preparing the liposomes, and the method of administering the formulation. Here are some key aspects:
- Composition Claims: These claims specify the components of the liposome formulation, including the type and amount of amikacin, the lipids used in the liposome, and any additional excipients.
- Method of Preparation Claims: These claims detail the steps involved in preparing the liposome formulation, including the process of encapsulating amikacin within the liposomes.
- Method of Administration Claims: These claims describe how the formulation is to be administered, including the dosage and the inhalation device used[2].
Detailed Claims Analysis
Independent Claims
- Independent claims are those that stand alone and define the invention without reference to other claims. For example, Claim 1 might describe the composition of the amikacin liposome inhalation suspension, including the specific lipids and the amount of amikacin encapsulated.
Dependent Claims
- Dependent claims build upon the independent claims and provide additional details or limitations. For instance, a dependent claim might specify a particular method of preparing the liposomes or a specific dosage regimen.
Patent Landscape
Related Patents
- Insmed Incorporated holds a series of patents related to Arikayce®, each with different expiration dates and covering various aspects of the product. For example:
- U.S. Patent No. 7,718,189
- U.S. Patent No. 8,226,975
- U.S. Patent No. 9,566,234
- U.S. Patent No. 9,895,385
- And several others, including international counterparts[2].
Global Dossier and International Filings
- The patent is part of a global patent family, with filings in various jurisdictions. The Global Dossier service provided by the USPTO allows users to view the file histories of related applications from participating IP Offices, including the IP5 Offices (USPTO, EPO, JPO, KIPO, and CNIPA)[1].
Search and Analysis Tools
Patent Public Search
- The USPTO's Patent Public Search tool can be used to find detailed information about this patent, including the full text of the patent, drawings, and any office actions or citations[1].
Common Citation Document (CCD)
- The CCD application consolidates prior art cited by all participating offices for the family members of a patent application, allowing for a comprehensive view of the prior art landscape related to this patent[1].
Economic and Technological Trends
Patenting Trends
- The USPTO data shows that patents in the pharmaceutical and biotechnology fields are significant indicators of innovation. The number of patents granted in these fields has been increasing, reflecting advancements in drug delivery systems and therapeutic formulations[4].
Industry Impact
- Patents like 8,679,532 play a crucial role in protecting intellectual property and encouraging innovation in the pharmaceutical industry. They provide exclusive rights to the patent holder, allowing them to recoup investment in research and development[4].
Key Takeaways
- Patent Scope: The patent covers a specific formulation of amikacin liposome inhalation suspension, including its composition, preparation method, and administration.
- Claims Analysis: The patent includes independent and dependent claims that define the invention and its various aspects.
- Patent Landscape: The patent is part of a broader portfolio held by Insmed Incorporated, with international filings and a global patent family.
- Search and Analysis Tools: Tools like the USPTO's Patent Public Search and the Common Citation Document (CCD) are essential for analyzing the patent and its prior art.
FAQs
Q: What is the main subject of United States Patent 8,679,532?
- The main subject is an Amikacin Liposome Inhalation Suspension, a formulation for treating bacterial infections.
Q: When does the patent expire?
- The patent is set to expire on December 5, 2026.
Q: How can I find more information about this patent?
- You can use the USPTO's Patent Public Search tool or visit the USPTO Public Search Facility.
Q: Is this patent part of a global patent family?
- Yes, it is part of a global patent family with filings in various jurisdictions.
Q: What are the economic implications of this patent?
- The patent protects Insmed Incorporated's intellectual property, allowing them to recoup investment in research and development and encouraging further innovation in the pharmaceutical industry.
Sources
- USPTO - Search for patents [USPTO]
- Insmed - Program Patents [Insmed]
- USPTO - Patent Claims Research Dataset [USPTO]
- NSF - Invention: U.S. and Comparative Global Trends [NSF]
More… ↓
⤷ Subscribe
|
